Crypto · IPO · Market Intelligence

Clear Signals for Market Momentum

Track IPOs, private companies, and crypto-related market movements in one modern intelligence platform.

Explore Data

SKN | Zoar Listing and Guerrilla RF Uplisting Lead a Fund-Heavy U.S. Market Calendar

Date:

Key Points:

  • November 18’s calendar includes 13 expected listing events, but most involve exchange-traded funds rather than traditional corporate IPOs.
  • Zoar Limited’s NYSE American debut follows the completion of its business combination with Impact Biomedical, giving the transaction a different structure from a conventional IPO.
  • Guerrilla RF’s Nasdaq uplisting provides an additional example of an established public company seeking broader market visibility without conducting a new share offering.

ETF Launches Account for Most Scheduled Activity

The November 18 U.S. IPO calendar records 13 expected pricing events, although the composition of the list offers a more measured picture of equity issuance. Most entries are exchange-traded funds, while the two most notable corporate names, Zoar Limited and Guerrilla RF, are entering or expanding their presence on U.S. exchanges through transactions that differ from conventional IPOs. The distinction is important: ETF launches broaden the range of publicly traded investment products, while corporate listings and business combinations provide separate signals about companies’ access to public equity markets.

Zoar’s Business Combination Creates a New Public-Market Structure

Zoar Limited is among the day’s most consequential corporate developments. The company completed its business combination with Impact Biomedical Inc., with Zoar’s ordinary shares expected to begin trading on the NYSE American under the symbol ZOAR on November 18. Impact Biomedical became a wholly owned subsidiary of Zoar following the transaction. The structure gives Zoar access to the U.S. public market through a completed business combination rather than a conventional underwritten IPO.

The operating business behind the transaction is focused on pharmaceutical manufacturing, including complex active pharmaceutical ingredients and intermediates. Zoar Labs, its operating subsidiary, reported fiscal-year revenue of $651.7 million and net income of $77.7 million for the year ended March 31, 2026. Those figures provide an initial indication of the business’s scale and reported profitability, although investors will need to examine the company’s financial disclosures, ownership structure and integration plans to assess the durability of those results.

The transaction is particularly relevant because it brings an established operating business into the U.S. public-market environment through a corporate combination. Its subsequent trading performance and the market’s assessment of its financial reporting will be more informative than the calendar’s expected-listing designation alone.

Guerrilla RF’s Nasdaq Move Highlights the Importance of Exchange Access

Guerrilla RF, a developer of radio-frequency and microwave semiconductors, was scheduled to begin trading on the Nasdaq Capital Market under its existing ticker, GUER, after receiving approval to transfer from the OTCQX market. The company announced the uplisting on November 17, describing it as part of its broader growth strategy.

The move does not represent a traditional IPO or a new capital raise. It is an exchange transfer intended to place the company’s shares on a major national securities exchange. Nasdaq access may improve visibility and broaden the potential investor base, although it does not guarantee stronger liquidity, higher valuation or increased institutional participation.

A related SEC filing disclosed that 22,000 outstanding Series A convertible preferred shares automatically converted into approximately 7.21 million common shares immediately before the Nasdaq listing. The conversion generated no additional proceeds for the company. This distinction matters when assessing the capital structure: the change increased common shares outstanding but did not provide fresh financing.

ETF Providers Continue to Expand Specialized Investment Strategies

The remaining calendar entries reinforce the importance of product development in the U.S. listing market. Identified launches include the Global X China Semiconductor ETF (CCHP), IncomeQ Nasdaq-100 Premium Income ETF (IQQI) and KICK Space Data Center and Infrastructure Index ETF (SDC). These products connect investor demand to themes spanning semiconductor supply chains, income-oriented equity strategies and digital infrastructure.

Other entries identify fund sponsors or trusts, including BlackRock ETF Trust, Global X Funds, Direxion Shares ETF Trust, Listed Funds Trust, Yorkville America Investment Trust and Amplify ETF Trust. However, the calendar does not provide complete fund names or investment objectives for every symbol. Their specific strategies and risk profiles therefore cannot be assessed reliably from the available listing information.

What the IPO Market Is Watching Next

The next meaningful signal will come from confirmed trading activity, rather than the number of scheduled calendar entries. Zoar’s market reception will test investor appetite for a newly combined operating business, while Guerrilla RF’s Nasdaq performance may indicate whether an exchange upgrade improves market access. For ETF launches, attention will turn to trading liquidity, assets gathered and the ability of specialized strategies to attract sustained investor interest.

SHARE POST

Subscribe

Popular

More like this
Related

SKN | Mahanadi Coalfields Secures $245 Million From Anchor Investors Ahead of IPO

Mahanadi Coalfields, a subsidiary of state-owned Coal India, has...

SKN | IPO-Bound Aragen Life Sciences Plans $160 Million Expansion Over Three Years

Aragen Life Sciences plans to invest approximately 15 billion...

SKN | Guerrilla RF Uplists Common Stock to Nasdaq Capital Market Under Ticker GUER

Radio-frequency semiconductor supplier Guerrilla RF, Inc. begins trading on...

SKN | Zoar Limited Advances NYSE American Listing Following Impact Biomedical Merger Approval

Pharmaceutical developer and manufacturer Zoar Limited is advancing toward...